Zacks Research Analysts Increase Earnings Estimates for PCRX

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Investment analysts at Zacks Research increased their FY2024 earnings estimates for shares of Pacira BioSciences in a research report issued on Tuesday, January 14th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $2.63 per share for the year, up from their prior forecast of $2.60. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q4 2024 earnings at $0.61 EPS, Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.56 EPS, Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.36 EPS, Q1 2026 earnings at $0.63 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.66 EPS, Q4 2026 earnings at $0.79 EPS and FY2026 earnings at $2.72 EPS.

A number of other equities analysts have also issued reports on the company. Jefferies Financial Group upped their target price on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday. Needham & Company LLC increased their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Finally, Barclays reduced their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.50.

Pacira BioSciences Stock Up 1.4 %

Shares of NASDAQ PCRX opened at $22.36 on Friday. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -11.01 and a beta of 0.76. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $34.01. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock’s 50-day simple moving average is $18.71 and its 200-day simple moving average is $17.51.

Hedge Funds Weigh In On Pacira BioSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of PCRX. Nisa Investment Advisors LLC boosted its position in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares during the period. CWM LLC grew its position in Pacira BioSciences by 713.6% in the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after buying an additional 5,716 shares in the last quarter. Virtus Investment Advisers Inc. acquired a new position in Pacira BioSciences during the 3rd quarter valued at about $98,000. China Universal Asset Management Co. Ltd. increased its stake in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after buying an additional 3,404 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Pacira BioSciences in the 2nd quarter worth approximately $140,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.